Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
9.39
-0.28 (-2.90%)
Jul 10, 2026, 12:52 PM EDT - Market open
Cartesian Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -151.77 | -130.3 | -77.42 | -219.71 | 35.38 | -25.69 |
Depreciation & Amortization | 2.42 | 2.96 | 1.15 | 0.84 | 1.29 | 1.25 |
Stock-Based Compensation | 10.44 | 10.52 | 6.58 | 22.52 | 11.19 | 7.72 |
Other Adjustments | 17.36 | 50.94 | 51.81 | 140.21 | -19.11 | 4.53 |
Change in Receivables | 1.5 | -0.24 | 7.98 | 0.91 | 0.16 | -2.69 |
Changes in Accounts Payable | -0.44 | 1.07 | -2.93 | 2.83 | 0.09 | -0.22 |
Changes in Accrued Expenses | -2.26 | -3.59 | -6.74 | -2.76 | 2.21 | 1.06 |
Changes in Income Taxes Payable | - | - | - | - | -0.6 | 0.6 |
Changes in Unearned Revenue | - | - | -5.85 | 5.26 | -64.71 | -45.5 |
Changes in Other Operating Activities | 0.29 | -5.3 | 1.75 | -1.27 | 2.47 | -1.45 |
Operating Cash Flow | -72.97 | -73.94 | -23.67 | -51.16 | -31.63 | -60.38 |
Capital Expenditures | -4.41 | -5.45 | -9.09 | -0.21 | -1.2 | -1.09 |
Sale of Property, Plant & Equipment | - | - | 0.35 | - | - | - |
Purchases of Investments | - | - | - | - | -33.5 | -32.46 |
Proceeds from Sale of Investments | - | - | - | 28.25 | 19.7 | 16.4 |
Other Investing Activities | - | - | - | 6.56 | - | - |
Investing Cash Flow | -4.41 | -5.45 | -8.74 | 34.61 | -15 | -17.14 |
Long-Term Debt Repaid | - | - | - | -27.46 | - | - |
Net Long-Term Debt Issued (Repaid) | - | - | - | -27.46 | - | - |
Issuance of Common Stock | 15.76 | 0.32 | 128.49 | 0.23 | 39.33 | 52.9 |
Repurchase of Common Stock | - | - | - | -6.17 | - | - |
Net Common Stock Issued (Repurchased) | 15.76 | 0.32 | 128.49 | -5.94 | 39.33 | 52.9 |
Issuance of Preferred Stock | - | - | 40 | 20.25 | - | - |
Net Preferred Stock Issued (Repurchased) | - | - | 40 | 20.25 | - | - |
Other Financing Activities | -0.17 | -8.38 | -0.07 | - | -0.11 | - |
Financing Cash Flow | 15.69 | -8.06 | 168.43 | -13.15 | 39.22 | 52.9 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.01 | 0.05 | -0.02 | -0.05 | 0.02 | -0 |
Net Cash Flow | -61.73 | -87.41 | 135.99 | -29.75 | -7.4 | -24.63 |
Free Cash Flow | -77.37 | -79.4 | -32.77 | -51.37 | -32.83 | -61.47 |
FCF Margin | -4359.10% | -2838.58% | -84.21% | -197.53% | -29.64% | -72.25% |
Free Cash Flow Per Share | -2.94 | -3.06 | -1.89 | -0.35 | -0.23 | -0.54 |
Levered Free Cash Flow | 8.85 | -140.62 | -99.14 | -242.47 | -25.07 | -71.02 |
Unlevered Free Cash Flow | -26.22 | -144.27 | -65.77 | -74.84 | -45.65 | -57.48 |